Company news

Natera, Inc. news in 2026

Natera, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Two Publications Highlight Clinical Utility of Signatera™ in Anal and Rectal Cancers

March 15, 2026

Natera Announces Commercial Launch of Zenith Genomics for Rare Disease Diagnosis

March 13, 2026

Natera Announces Commercial Launch of Zenith™ Genomics for Rare Disease Diagnosis

March 11, 2026

MyOme Debuts Zenith™ Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026

March 11, 2026

Signatera™ MRD Data at ASCO GU Highlights Potential Utility Across GU Cancers, Including for Bladder Preservation

February 27, 2026

Natera Reports Fourth Quarter and Full Year 2025 Financial Results

February 25, 2026

Successful Readout of Prospective Phase 2 SINERGY Trial Supports SignateraTM MRD-Guided Treatment in Head and Neck Cancer

February 23, 2026

Natera to Report its Fourth Quarter and Full Year Results on February 26, 2026

February 16, 2026

Natera Launches EDEN Study on Early Risk Assessment for Preeclampsia and Adverse Pregnancy Outcomes

February 5, 2026

Natera Submits Signatera™ CDx PMA to FDA

February 1, 2026

Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation

January 27, 2026

Prospera™ Featured in Landmark Interventional Study Advancing Lung Transplant Care

January 25, 2026

Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer

January 20, 2026

Natera’s Fetal Focus™ Single Gene NIPT (sgNIPT) Selected for Prestigious Oral Plenary Presentation at Society of Maternal Fetal Medicine (SMFM) Meeting

January 19, 2026

Natera Announces Next Breakthrough in MRD-Based Risk Stratification, Leveraging Multi-Modal AI Modeling

January 12, 2026

Natera to Scale AI Foundation Models in Precision Medicine with NVIDIA

January 11, 2026

Natera Announces Strong Preliminary Fourth Quarter and 2025 Financial Results Driven by Record Signatera™ Growth

January 11, 2026

Dr. Paul Billings Joins Lindus Health's Scientific Advisory Board

January 8, 2026

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

January 6, 2026

Natera Presents Updated Analyses From ALTAIR Clinical Trial at ASCO GI

January 4, 2026

Natera Launches 21-Gene Fetal Focus™ Single-Gene NIPT, Powered By Ultra-Sensitive LinkedSNP™ Technology

January 4, 2026

← Newer news releases

Calls in 2026

Decks in 2026